Study On The Clinical Efficacy Of Rivaroxaban In The Treatment Of Venous Thromboembolism

Objective: Analysis of clinical indicators associated with rivaroxaban and traditional anticoagulant drugs,low molecular weight heparin calcium,in the treatment of venous thromboembolism.Compare the clinical efficacy of two treatments for venous thromboembolism.Methods: The subjects of this study were selected from the Department of Vascular Surgery,Chifeng Municipal Hospital from September 2017 to September 2018.A total of 80 patients with venous thromboembolism and compliance with the inclusion criteria were diagnosed by lower extremity venous color Doppler ultrasound,pulmonary CT,and D-dimer.According to the patient’s informed situation and choose an anticoagulant treatment plan.According to the different drugs used in the initial anticoagulation program,they were divided into two groups:group A: 40 patients in the traditional anticoagulant group,and group B: 40 patients in the rivaroxaban group.All patients were recorded before the treatment,30 days,90 days of treatment,the patient’s limb circumference difference,D-dimer level,the affected limb percutaneous oxygen partial pressure,venous patency score and adverse reactions;pulmonary artery CT was performed in patients with deep venous thrombosis of lower extremity and pulmonary embolism,and thrombus ablation and adverse reactions were recorded.Statistical methods were used to analyze the follow-up data of the two groups of patients to compare the clinical efficacy of the two treatments.Results: A total of 80 patients were enrolled,and 10 patients were lost to follow-up.The rate of loss of follow-up was 12.5%.At the end of follow-up,the circumferential diameter difference of the 15 cm limb of the rivaroxaban group and the traditional anticoagulant group was 1.02±0.40 cm and 1.24±0.41 cm,respectively.The circumferential diameter difference of the 15 cm limbs under the knee was 0.99±0.21 cm and 1.18±0.20 cm,respectively.The difference between the two groups was statistically significant(P<0.05).The D-dimer was273.40±54.50μg/L and 329.10±49.05μg/L,respectively.The difference between the two groups was statistically significant.The percutaneous oxygen partial pressure was58.13±11.22 mmHg and 52.38±10.84 mmHg,respectively.There was a statisticallysignificant difference between the two groups(P<0.05).The total effective rate of treatment for patients with pulmonary embolism was 83.3% and 80.0%,respectively.There was no significant difference between the two groups(P>0.05).At the end of follow-up,there were 3clinically relevant bleeding events in the traditional anticoagulant group and 1 clinically relevant bleeding event in the rivaroxaban group.Two cases of recurrence occurred in the traditional anticoagulant group and one case occurred in the rivaroxaban group.Conclusion: 1.Rivaroxaban is superior to traditional anticoagulant drugs in the treatment of VTE.2.The risk of bleeding and recurrence of rivaroxaban in the treatment of VTE is lower than that of traditional anticoagulant drugs.3.Rivaroxaban is superior to traditional anticoagulant drugs in improving the percutaneous oxygen partial pressure of local microcirculation.